<DOC>
	<DOCNO>NCT01916850</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability multiple oral dos LX4211 400 mg LX4211 800 mg ( administer daily 10 consecutive day ) healthy subject .</brief_summary>
	<brief_title>Study Determine Safety , Tolerability Pharmacokinetics Following Multiple Doses LX4211 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Adult subject ≥ 18 ≤ 55 year age Vital sign Screening follow range : systolic blood pressure , 90140 mm Hg ; diastolic blood pressure , 5090 mm Hg ; heart rate , 50100 bpm Body mass index ( BMI ) ≥18 ≤35 kg/sq Willing able provide write informed consent Use medication ( prescription , overthecounter , herbal tea , supplement ) within 5 day dose Use investigational agent study treatment within 30 day dose Use protein antibodybased therapeutic agent within 3 month Screening Prior exposure LX4211 Use cigarettes tobacco product within 2 month prior Screening participate study History bariatric surgery gastrointestinal surgery may induce malabsorption History major surgery within 6 month Screening History hypersensitivity inactive component LX4211 History renal disease significantly abnormal kidney function test History hepatic disease significantly abnormal liver function test History active infection within 14 day prior Day 1 History alcohol substance abuse within 2 year prior Day 1 Donation loss &gt; 400 mL blood blood product within 3 month dose Positive urine glucose Screening Positive urine screen drug abuse , urine test alcohol Screening Day 1 Inability difficulty swallow pill Unable unwilling communicate cooperate Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>